Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.
Raj N, Zheng Y, Kelly V, Katz S, Chou J, Do R, Capanu M, Zamarin D, Ariyan C, Untch B, O'Reilly E, Gopalan A, Berger M, Olino K, Segal N, Reidy D. Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma. Journal Of Clinical Oncology 2019, 37: 4112-4112. DOI: 10.1200/jco.2019.37.15_suppl.4112.Peer-Reviewed Original ResearchAdvanced adrenocortical carcinomaSafety of pembrolizumabAdrenocortical carcinomaPD-L1Germline next-generation sequencingMedian tumor mutation burdenPhysician/patient decisionTumor PD-L1 positivityTumor PD-L1 statusMedian age 62Treatment-related AEsTumor PD-L1PD-L1 positivityPD-L1 statusSingle-center studyTumor mutation burdenAvailable tumor samplesMutations/megabaseECOG 0LFT elevationsMedian DoRMedian OSMedian PFSIntolerable toxicityPrimary endpoint